These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
299 related items for PubMed ID: 11406542
1. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH. Cancer Res; 2001 Jun 15; 61(12):4716-22. PubMed ID: 11406542 [Abstract] [Full Text] [Related]
2. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL. Cancer Res; 2002 Aug 01; 62(15):4263-72. PubMed ID: 12154028 [Abstract] [Full Text] [Related]
3. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, Begent RH. Cancer Res; 1996 Jul 15; 56(14):3293-300. PubMed ID: 8764124 [Abstract] [Full Text] [Related]
4. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. Clin Cancer Res; 2000 Sep 15; 6(9):3621-8. PubMed ID: 10999754 [Abstract] [Full Text] [Related]
5. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts. Wilder RB, Langmuir VK, Mendonca HL, Goris ML, Knox SJ. Cancer Res; 1993 Jul 01; 53(13):3022-7. PubMed ID: 8319209 [Abstract] [Full Text] [Related]
6. Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts. Ng B, Kramer E, Liebes L, Wasserheit C, Hochster H, Blank E, Ceriani R, Furmanski P. Cancer Res; 2001 Apr 01; 61(7):2996-3001. PubMed ID: 11306478 [Abstract] [Full Text] [Related]
7. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y. Cancer Res; 2000 Oct 01; 60(19):5565-70. PubMed ID: 11034104 [Abstract] [Full Text] [Related]
8. Comparative toxicity and efficacy of combined radioimmunotherapy and antiangiogenic therapy in carcinoembryonic antigen-expressing medullary thyroid cancer xenograft. Kraeber-Bodéré F, Bodet-Milin C, Niaudet C, Saï-Maurel C, Moreau A, Faivre-Chauvet A, Thomare P, Deleris G, Estieu-Gionnet K, Bikfalvi A, Barbet J, Paris F. J Nucl Med; 2010 Apr 01; 51(4):624-31. PubMed ID: 20351352 [Abstract] [Full Text] [Related]
9. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49. Buchsbaum D, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M, Meredith R. Cancer Res; 1995 Dec 01; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364 [Abstract] [Full Text] [Related]
10. Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy. Dearling JL, Qureshi U, Begent RH, Pedley RB. Clin Cancer Res; 2007 Mar 15; 13(6):1903-10. PubMed ID: 17363547 [Abstract] [Full Text] [Related]
11. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH. Cancer Res; 1999 Aug 15; 59(16):3998-4003. PubMed ID: 10463598 [Abstract] [Full Text] [Related]
12. Predicting response to radioimmunotherapy from the tumor microenvironment of colorectal carcinomas. El Emir E, Qureshi U, Dearling JL, Boxer GM, Clatworthy I, Folarin AA, Robson MP, Nagl S, Konerding MA, Pedley RB. Cancer Res; 2007 Dec 15; 67(24):11896-905. PubMed ID: 18089820 [Abstract] [Full Text] [Related]
15. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model. Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL. Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357 [Abstract] [Full Text] [Related]
16. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Holwell SE, Cooper PA, Thompson MJ, Pettit GR, Lippert LW, Martin SW, Bibby MC. Anticancer Res; 2002 Oct 15; 22(6C):3933-40. PubMed ID: 12553015 [Abstract] [Full Text] [Related]
17. Combined radioimmunotherapy and radiotherapy of human colon carcinoma grafted in nude mice. Buchegger F, Rojas A, Delaloye AB, Vogel CA, Mirimanoff RO, Coucke P, Sun LQ, Raimondi S, Denekamp J, Pèlgrin A. Cancer Res; 1995 Jan 01; 55(1):83-9. PubMed ID: 7805046 [Abstract] [Full Text] [Related]
19. Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer. Cardillo TM, Ying Z, Gold DV. Clin Cancer Res; 2001 Oct 01; 7(10):3186-92. PubMed ID: 11595713 [Abstract] [Full Text] [Related]
20. Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice, advantages and limitations. Chalandon Y, Mach JP, Pèlegrin A, Folli S, Buchegger F. Anticancer Res; 1992 Oct 01; 12(4):1131-9. PubMed ID: 1503403 [Abstract] [Full Text] [Related] Page: [Next] [New Search]